AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

20142,655 citationsJournal Articlebronze Open Access

Authors

Emmanuel S. Antonarakis · Johns Hopkins University

Changxue Lu · Johns Hopkins University

Hao Wang · Johns Hopkins University

Brandon Luber · Johns Hopkins Medicine

Mari Nakazawa · Johns Hopkins Medicine

Jeffrey C. Roeser · Johns Hopkins Medicine

Yan Chen ·

Abstract

Detection of AR-V7 in circulating tumor cells from patients with castration-resistant prostate cancer may be associated with resistance to enzalutamide and abiraterone. These findings require large-scale prospective validation. (Funded by the Prostate Cancer Foundation and others.).

Topics & Keywords

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Hormonal and reproductive studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 371, Issue 11, pp. 1028-1038

DOI: 10.1056/nejmoa1315815

Field-Weighted Citation Impact: 215.77